OncoMatch/Clinical Trials/NCT04993690
A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
Is NCT04993690 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies LP-168 tablet for b-cell lymphoma.
Treatment: LP-168 tablet — This is an open-label, multi-center Phase 1/2 study of oral LP-168 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Prior therapy
Must have received: standard of care
DLBCL or FL...have received 2 lines SOC
Must have received: standard of care
non-Hodgkin's lymphoma associated with B-cell proliferation...have received 1 line SOC
Cannot have received: antitumor therapies including myelosuppressive chemotherapy, targeted therapy, biological therapy and/or immunotherapy
Subjects who have received the following treatments within 4 weeks or 5 half-lives before the first dose of LP-168: Antitumor therapies including myelosuppressive chemotherapy, targeted therapy, biological therapy and/or immunotherapy
Cannot have received: investigational treatment
Any investigational treatment
Cannot have received: major surgery, severe trauma or radiotherapy
Patients who have undergone major surgery, severe trauma or radiotherapy
Cannot have received: steroids or traditional herbal medicine for antitumor purposes
Steroids or traditional herbal medicine for antitumor purposes
Lab requirements
Blood counts
Adequate hematologic function
Kidney function
Adequate renal function
Liver function
Adequate hepatic function
Adequate hematologic function. Adequate hepatic and renal function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify